AMGN vs SMMT
AMGN: Amgen is a leading biotechnology firm dedicated to developing innovative human therapeutics to address critical unmet needs in areas like oncology, inflammation, and cardiovascular disease. SMMT: A biopharmaceutical company dedicated to the clinical advancement of its lead bispecific antibody, ivonescimab, for oncology applications.
Side-by-side fundamentals
| Metric | AMGN | SMMT | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $390.02 | $13.10 | |
| Market cap as of 2026-08-05 | $210.5B | $10.5B | |
| P/E as of 2026-08-05 | 26.27 | n/a | |
| PEG as of 2026-08-05 | 5.48 | -1.05 | SMMT lower |
| Net margin as of 2026-08-05 | +21.0% | -9027.1% | AMGN higher |
| Gross margin as of 2026-08-05 | +74.0% | n/a | |
| Operating margin as of 2026-08-05 | +28.8% | -8108.3% | AMGN higher |
| ROE as of 2026-08-05 | +89.4% | -168.9% | AMGN higher |
| ROA as of 2026-08-05 | +8.6% | -141.9% | AMGN higher |
| Debt / equity as of 2026-08-05 | 6.24 | 0.00 | SMMT lower |
| Revenue growth (YoY) as of 2026-08-05 | +9.1% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +11.8% | n/a | |
| Dividend yield as of 2026-08-05 | +2.7% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-05 | 0.40 | -1.34 | |
| 1-year return as of 2026-08-04 close | +29.2% | -54.3% | AMGN higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.